Landín (MX) Cancer Clinical Trials

A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

~48 mi. (Santiago de Querétaro, Mexico, +144 more cities)

Cuidados Oncologicos ( Site 0608)

Clear Cell Renal Cell Carcinoma

belzutifan, +3 more drugs

immunotherapy, +1 more type

Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)

~48 mi. (Santiago de Querétaro, Mexico, +105 more cities)

Cuidados Oncologicos ( Site 2908)

ATM Loss, +62 more biomarkers

Breast Carcinoma, +2 more conditions

olaparib

targeted therapy

Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma

~48 mi. (Santiago de Querétaro, Mexico, +34 more cities)

Cuidados Oncologicos

Clear Cell Renal Cell Carcinoma

nivolumab, +1 more drug

immunotherapy, +1 more type

Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)

~48 mi. (Santiago de Querétaro, Mexico, +115 more cities)

Cuidados Oncologicos ( Site 3104)

ATM Loss, +27 more biomarkers

Breast Carcinoma, +2 more conditions

olaparib, +1 more drug

immunotherapy, +1 more type